Table 3.

LMTK3 polymorphisms and survival in Japanese cohort by gender

DFSOS
nMedian, yrs (95% CI)HR (95% CI)HR (95% CI)dMedian, yrs (95% CI)HR (95% CI)HR (95% CI)d
LMTK3 polymorphisms and DFS and OS in Japanese male patients with gastric cancer
LMTK3 rs8108419
 A/Aa4
 A/Ga262.3 (1.2–20.1c)1 (Reference)1 (Reference)20.1c (2.3–20.1c)1 (Reference)1 (Reference)
 G/G784.8 (2.0–15.2c)0.86 (0.47–1.57)0.79 (0.42–1.47)5.7 (3.4–15.2c)0.98 (0.51–1.91)0.86 (0.43–1.70)
Pb0.620.460.960.66
LMTK3 rs9989661
 C/Ca53
 C/Ta3720.1c (2.4–20.1c)1 (Reference)1 (Reference)20.1c (3.9–20.1c)1 (Reference)1 (Reference)
 T/T180.9 (0.3–6.1c)2.05 (1.05 4.00)4.37 (2.08–9.18)1.7 (0.6–6.1c)2.07 (1.02–4.20)3.69 (1.65–8.24)
Pb0.030<0.00010.0390.0014
LMTK3 polymorphisms and DFS and OS in Japanese female patients with gastric cancer
LMTK3 rs8108419
 A/Aa4
 A/Ga172.5 (1.6–16.1c)1 (Reference)1 (Reference)3.4 (1.8–16.1c)1 (Reference)1 (Reference)
 G/G3615.4c (1.9–15.4c)0.88 (0.40–1.95)2.12 (0.80–5.61)15.4c (2.3–15.4c)0.95 (0.42–2.15)3.04 (1.08–8.56)
Pb0.760.130.900.035
LMTK3 rs9989661
 C/Ca19
 C/Ta2715.4c (1.9–15.4c)1 (Reference)1 (Reference)3.4 (2.3–15.4c)1 (Reference)1 (Reference)
 T/T1316.1c (0.7–16.1c)1.13 (0.46–2.79)0.92 (0.36–2.34)16.1c (0.9–16.1c)0.92 (0.35–2.44)0.71 (0.26–1.92)
Pb0.790.860.870.50
  • aCombined in the analysis in the dominant or recessive model.

  • bOn the basis of the log-rank test in the univariate analysis and Wald test in the multivariate analysis within Cox regression model.

  • cEstimates were not reached.

  • dAdjusted for stage (I, II, III, and IV as categorical), age (<65, 65–74, ≥75 years as ordinal), and type of adjuvant therapy (no vs. yes).